STOCK TITAN

Kura Oncology to Report First Quarter 2022 Financial Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) announced that it will release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call with management will take place at 4:30 p.m. ET to discuss the results and provide a corporate update. The call can be accessed via phone or streamed online. Kura Oncology focuses on precision cancer treatments and has multiple clinical trials underway, including Ziftomenib for relapsed AML and Tipifarnib for HRAS mutant HNSCC.

Positive
  • Multiple ongoing clinical trials targeting key cancer pathways.
  • Ziftomenib in Phase 1b for relapsed/refractory AML.
  • Tipifarnib received Breakthrough Therapy Designation.
Negative
  • None.

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial results after the close of U.S. financial markets on Wednesday, May 4, 2022. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (844) 826-3035 for domestic callers and (412) 317-5195 for international callers and entering the conference code: 10166202. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.
        
About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib (KO-539), a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed trial (AIM-HN) in patients with this devastating disease. In addition, Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients, including those whose tumors are dependent on HRAS and/or PI3Kα pathways. The Company is also developing KO-2806, a next-generation FTI, which is intended to target innovative biology and larger oncology indications through combination regimens. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Senior Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
ICR Westwicke
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com


FAQ

When will Kura Oncology report its first quarter 2022 financial results?

Kura Oncology will report its first quarter 2022 financial results on May 4, 2022.

What time is Kura Oncology's financial call on May 4, 2022?

The financial call will be held at 4:30 p.m. ET on May 4, 2022.

How can I access the Kura Oncology conference call?

The conference call can be accessed by dialing (844) 826-3035 for domestic callers or (412) 317-5195 for international callers.

What is Kura Oncology's focus in cancer treatment?

Kura Oncology focuses on precision medicines targeting cancer signaling pathways.

Kura Oncology, Inc.

NASDAQ:KURA

KURA Rankings

KURA Latest News

KURA Stock Data

1.24B
76.18M
1.05%
105.32%
12.13%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO